Manish Pandya, MD
Nephrology · Farmington, NMNPI 1326145392
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (56.9%), food and beverage and education — rather than concentrated in one kind of arrangement. Vantive US Healthcare LLC accounts for 60.5% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $1,290, more than ten times the $85 reported in 2019.
Across 43 payments — averaging $46.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vantive US Healthcare LLC$1K
- Amgen$127
- Mozarc Medical US LLC$123
- Novo Nordisk$87
- AstraZeneca$69
- Medtronic$65
- plus $313 from 11 others
What the payments were for
- Travel & lodging$1,12957%
- Food & beverage$77939%
- Education$754%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vantive US Healthcare LLC | 7 | $1,199 |
| Amgen | 4 | $127 |
| Mozarc Medical US LLC | 1 | $123 |
| Novo Nordisk | 5 | $87 |
| AstraZeneca | 5 | $69 |
| Medtronic | 3 | $65 |
| Bayer | 3 | $57 |
| Lilly USA, LLC | 3 | $53 |
| GSK | 2 | $38 |
| Aurinia Pharma U.S., Inc. | 2 | $29 |
| Travere Therapeutics, Inc. | 2 | $28 |
| Calliditas Therapeutics US Inc. | 1 | $26 |
| Insulet Corporation | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $14 |
| Novartis | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - Chronic$1,129
- Chameleon$123
How this compares
$1,983 in reported general payments places this provider in the 60th percentile of 68 nephrology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Thiola EcTiopronin | 12 | $127,226 |
| JardianceEmpagliflozin | 36 | $29,324 |
| TrulicityDulaglutide | 18 | $28,547 |
| XareltoRivaroxaban | 24 | $25,251 |
| EliquisApixaban | 24 | $22,311 |
| Cinacalcet Hcl | 17 | $8,581 |
| FarxigaDapagliflozin Propanediol | 15 | $8,472 |
| Envarsus XrTacrolimus | 14 | $6,689 |
| Calcium Acetate | 92 | $5,856 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $5,092 |
| Sevelamer Carbonate | 29 | $4,032 |
| Nifedipine ErNifedipine | 157 | $3,858 |
| Carvedilol | 343 | $3,476 |
| Tamsulosin Hcl | 126 | $2,685 |
| Lisinopril | 302 | $2,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $53 | $28,54718 claims |
| AstraZenecaFarxiga | $69 | $8,47215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 68 nephrology providers in New Mexico.
Other nephrology in Farmington
- Kettia GuilliteFarmington$1K
- Daniel AdeneyeFarmington$786
- Franklin LamFarmington$779
- Mark BevanFarmington$149
- Satyaki BanerjeeAlbuquerque$260K
- Catalina VoinescuSanta Fe$41K
- Christos ArgyropoulosAlbuquerque$32K
- Arun RajasekaranAlbuquerque$32K
- Jose HenaoLas Cruces$31K
- George Vasquez RiosAlbuquerque$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.